Dana-Farber Cancer Institute
Jacqueline S. Garcia, MD

Jacqueline S. Garcia, MD

Medical Oncology
Top Doctor Award Badge
MAKE AN APPOINTMENT

Contact Information

Office Phone Number

617-632-1906

Fax

617-632-2933

Appointments

857-215-3262 (Inpatient Transfers)

On This Page

Biography

Jacqueline S. Garcia, MD

Dr. Jacqueline S. Garcia is a medical oncologist in the Adult Leukemia Program at the Dana-Farber Cancer Institute. She graduated from University of Illinois at Chicago College of Medicine and completed her internship and residency training in Internal Medicine at the University of Chicago. She next completed Hematology and Oncology Fellowship training at Stanford University. Dr. Garcia’s research focus is on the design and execution of scientifically-based early phase clinical and proof-of-concept studies in advanced myeloid malignancies, including myelodysplastic syndromes, myelofibrosis and acute myeloid leukemia. Much of her research centers on identifying novel therapeutic opportunities to leverage the anti-apoptotic pathway in chemoresistant leukemia and developing investigator-initiated trials.  Her research is supported by awards from the National Institutes of Health/National Cancer Institute, Leukemia and Lymphoma Society, and Conquer Cancer Foundation.

Researcher

Physician

Physician
Assistant Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School

Centers/Programs

Adult Leukemia Program

Clinical Interests

Acute myeloid leukemia, Leukemias, MDS, Myelodysplastic syndromes, Myelofibrosis, Myeloproliferative neoplasms

Diseases Treated

Board Certification

  • Hematology, 2014
  • Internal Medicine, 2011
  • Medical Oncology, 2015

Fellowship

  • Stanford University, CA, Hematology & Oncology

Residency

  • University of Chicago, IL, Internal Medicine

Medical School

  • University of Illinois at Chicago College of Medicine

Recent Awards

  • 2020: National Institutes of Health/National Cancer Institute, Clinical Investigator Award (K08)

Research

    View Dr. Garcia’s Research

     

    The focus of my research is to identify vulnerabilities of resistant myeloid leukemias (what makes cancer cell's vulnerable) and to exploit these vulnerabilities with selective therapies.

     

    Research Departments

    Support my research

    Publications

      View Dr. Garcia's Publications

      • The Development of FLT3 Inhibitors in Acute Myeloid Leukemia. Hematol Oncol Clin North Am. 2017 08; 31(4):663-680. View in: Pubmed

      • Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma. 2022 08; 63(8):1934-1941. View in: Pubmed

      • BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes. Blood Cancer Discov. 2022 03 01; 3(2):116-135. View in: Pubmed

      • Regulation of ribosomal gene expression in cancer. J Cell Physiol. 2015 Jun; 230(6):1181-8. View in: Pubmed

      • Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species. Clin Cancer Res. 2016 Apr 15; 22(8):1978-88. View in: Pubmed

      • The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. View in: Pubmed

      • Prospects for Venetoclax in Myelodysplastic Syndromes. Hematol Oncol Clin North Am. 2020 04; 34(2):441-448. View in: Pubmed

      • Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol. 2019 09; 32(9):1373-1385. View in: Pubmed

      • Monosomal karyotype acute myeloid leukemia: tread lightly. Acta Haematol. 2015; 133(4):324-6. View in: Pubmed

      • Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell. 2020 12 14; 38(6):872-890.e6. View in: Pubmed

      • Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Blood. 2023 03 16; 141(11):1265-1276. View in: Pubmed

      • Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leuk Lymphoma. 2016; 57(3):609-15. View in: Pubmed

      • Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia? Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):41-50. View in: Pubmed

      • Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell. 2021 03 04; 28(3):514-523.e9. View in: Pubmed

      • Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Adv. 2021 12 28; 5(24):5536-5545. View in: Pubmed

      • Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)]. Leuk Res. 2021 Jun; 105:106581. View in: Pubmed

      • Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. Exp Hematol. 2022 03; 107:14-19. View in: Pubmed

      • Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. J Clin Oncol. 2022 03 10; 40(8):855-865. View in: Pubmed

      • Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020 08 13; 383(7):617-629. View in: Pubmed

      • The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. View in: Pubmed

      • Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells. Oncotarget. 2016 Nov 15; 7(46):74917-74930. View in: Pubmed

      • EXABS-140-MDS Immune Therapy Approaches in MDS. Clin Lymphoma Myeloma Leuk. 2022 Oct; 22 Suppl 2:S50-S52. View in: Pubmed

      • Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. Clin Cancer Res. 2022 07 01; 28(13):2744-2752. View in: Pubmed

      • Blood consult: monosomal karyotype acute myeloid leukemia. Blood. 2012 Jun 14; 119(24):5659-60. View in: Pubmed

      • Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133. View in: Pubmed

      • Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget. 2018 Feb 20; 9(14):11665-11676. View in: Pubmed

      • A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol. 2023 02; 98(2):272-281. View in: Pubmed

      • A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. Leuk Res. 2021 05; 104:106555. View in: Pubmed

      • Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings. Blood. 2023 04 13; 141(15):1884-1888. View in: Pubmed

      • Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive. Drugs Today (Barc). 2017 Oct; 53(10):531-543. View in: Pubmed

      • Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. Am J Hematol. 2020 03; 95(3):245-250. View in: Pubmed

      • Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates. Clin Cancer Res. 2023 03 01; 29(5):878-887. View in: Pubmed

      • Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation. Leuk Res. 2023 02; 125:107004. View in: Pubmed

      • Considerations for Drug Development in Myelodysplastic Syndromes. Clin Cancer Res. 2023 07 14; 29(14):2573-2579. View in: Pubmed

      • Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood. 2023 04 27; 141(17):2047-2061. View in: Pubmed

      • BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia. Blood Adv. 2023 06 27; 7(12):2917-2923. View in: Pubmed

      • Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 2023 04 13; 141(15):1817-1830. View in: Pubmed

      • FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged =60 years. Blood Adv. 2023 09 26; 7(18):5354-5358. View in: Pubmed

      • A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies. Blood Cancer Discov. 2023 07 05; 4(4):276-293. View in: Pubmed

      • Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia. Leuk Res. 2023 09; 132:107351. View in: Pubmed

      • Optimization of Advanced Molecular Genetic Testing Utilization in Hematopathology: A Goldilocks Approach to Bone Marrow Testing. JCO Oncol Pract. 2024 02; 20(2):220-227. View in: Pubmed

      • Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024 02 13; 8(3):591-602. View in: Pubmed

      • Integrative genotyping of cancer and immune phenotypes by long-read sequencing. Nat Commun. 2024 01 02; 15(1):32. View in: Pubmed

      • Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML. Sci Transl Med. 2024 01 03; 16(728):eade2774. View in: Pubmed

      • Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv. 2024 02 27; 8(4):978-990. View in: Pubmed

      • Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial. Clin Lymphoma Myeloma Leuk. 2024 Jun; 24(6):364-374. View in: Pubmed

      • Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts. Blood Cancer Discov. 2024 May 01; 5(3):180-201. View in: Pubmed

      • Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024 04; 99(4):615-624. View in: Pubmed

      • Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies. Acta Haematol. 2024; 147(2):198-218. View in: Pubmed

      • Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia. 2024 Jul; 38(7):1494-1500. View in: Pubmed

      • Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect. Front Immunol. 2024; 15:1359113. View in: Pubmed

      • PhALLCON Soars to New Heights-Faster, Stronger, but Better? JAMA. 2024 06 04; 331(21):1805-1806. View in: Pubmed

      • Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. Leukemia. 2024 Sep; 38(9):1992-2002. View in: Pubmed

      • CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias. Blood. 2024 09 19; 144(12):1290-1299. View in: Pubmed

      • Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. Blood. 2025 02 06; 145(6):577-589. View in: Pubmed

      • A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2024 Nov 01; 30(21):4844-4855. View in: Pubmed

      • Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen. Blood Cancer J. 2024 10 31; 14(1):191. View in: Pubmed

      • Tracking Rare Single Donor and Recipient Immune and Leukemia Cells after Allogeneic Hematopoietic Cell Transplantation Using Mitochondrial DNA Mutations. Blood Cancer Discov. 2024 Nov 01; 5(6):442-459. View in: Pubmed

      • Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Adv. 2025 Feb 11; 9(3):617-626. View in: Pubmed

      • Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 2025 Mar 13; 145(11):1126-1135. View in: Pubmed

      • Advancing drug development in myelodysplastic syndromes. Blood Adv. 2025 Mar 11; 9(5):1095-1104. View in: Pubmed

      • Sharpening the Tools to Get the Edge on Leukemia. Am J Hematol. 2025 May; 100(5):750-751. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Boston, MA 02215
      Get Direction
      42.3374, -71.1083

      Ratings and Comments

      Jacqueline S. Garcia, MD

      About Our Ratings

      Physician Star Rating Comment Block

      Discovery and Insights

      Back to Top